Ryo Asaoka1, Hiroshi Murata1, Yuri Fujino1, Kazunori Hirasawa1,2, Masaki Tanito3,4, Shiro Mizoue5, Kazuhiko Mori6, Katsuyoshi Suzuki7, Takehiro Yamashita8, Kenji Kashiwagi9, Atsuya Miki10, Nobuyuki Shoji2. 1. Department of Ophthalmology, The University of Tokyo, Tokyo, Japan. 2. Orthoptics and Visual Science, Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan. 3. Department of Ophthalmology, Shimane University Faculty of Medicine, Shimane, Japan. 4. Division of Ophthalmology, Matsue Red Cross Hospital, Shimane, Japan. 5. Department of Ophthalmology, Ehime University Graduate School of Medicine, Ehime, Japan. 6. Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 7. Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. 8. Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 9. Department of Ophthalmology, University of Yamanashi Faculty of Medicine, Yamanashi, Japan. 10. Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
Abstract
BACKGROUND/AIM: To investigate the effects of ocular and systemic risk factors for glaucomatous progression in different sectors of the visual field (VF). METHOD: 409 eyes from 268 patients with 10 reliable VFs from the Japanese Archive of Multicentral Databases in Glaucoma (JAMDIG) were investigated. VFs were divided into six sectors (mean total deviation (mTD)s20+, mTDs10-20 and mTDs0-10, >20°, 10-20° and <10° in the superior hemifield, respectively; and mTDi20+, mTDi10-20 and mTDi0-10, >20°, 10-20° and <10° in the inferior hemifield, respectively). The relationship between sectorial progression rate and eight variables (age, mTD at baseline VF, average intraocular pressure (IOP), SD of IOP, systemic hypertension, migraine, family history of glaucoma and smoking status) was investigated. RESULT: The mTD progression rate was -0.21 dB/year. Older age was related to progression of mTDs20+, mTDs10-20, mTDi20+ and mTDi10-20. Mean IOP was not related to progression in any VF sector; however, a larger SD of IOP was related to progression of mTDs20+, mTDi0-10, mTDi10-20 and mTDi20+. Smoking status was related to progression in all inferior VF sectors (mTDi0-10, mTDi10-20 and mTDi20+). CONCLUSIONS: Smoking status is related to glaucomatous VF progression in all sectors of the inferior hemifield. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND/AIM: To investigate the effects of ocular and systemic risk factors for glaucomatous progression in different sectors of the visual field (VF). METHOD: 409 eyes from 268 patients with 10 reliable VFs from the Japanese Archive of Multicentral Databases in Glaucoma (JAMDIG) were investigated. VFs were divided into six sectors (mean total deviation (mTD)s20+, mTDs10-20 and mTDs0-10, >20°, 10-20° and <10° in the superior hemifield, respectively; and mTDi20+, mTDi10-20 and mTDi0-10, >20°, 10-20° and <10° in the inferior hemifield, respectively). The relationship between sectorial progression rate and eight variables (age, mTD at baseline VF, average intraocular pressure (IOP), SD of IOP, systemic hypertension, migraine, family history of glaucoma and smoking status) was investigated. RESULT: The mTD progression rate was -0.21 dB/year. Older age was related to progression of mTDs20+, mTDs10-20, mTDi20+ and mTDi10-20. Mean IOP was not related to progression in any VF sector; however, a larger SD of IOP was related to progression of mTDs20+, mTDi0-10, mTDi10-20 and mTDi20+. Smoking status was related to progression in all inferior VF sectors (mTDi0-10, mTDi10-20 and mTDi20+). CONCLUSIONS: Smoking status is related to glaucomatous VF progression in all sectors of the inferior hemifield. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.